Patient perceptions of treatment-free remission in chronic myeloid leukemia

Lucia A. Villemagne Sanchez, Clare O’Callaghan, Karla Gough, Karen Hall, Yoshihisa Kashima, John F. Seymour, Penelope Schofield, David Ross

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81% of participants (95% CI: 72%–89%) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest motivations for TFR included TKI toxicity (n = 26) and convenience (n = 18). The leading reason for reluctance was fear of consequences of stopping TKI (n = 16). Reluctance was often associated with needs for additional information or incomplete understanding of the current data. Understanding patient motivations and concerns is important if TFR is to become a part of CML management.

LanguageEnglish
Pages406-415
Number of pages10
JournalLeukemia and Lymphoma
Volume59
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • quality of life
  • treatment-free remission
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Villemagne Sanchez, L. A., O’Callaghan, C., Gough, K., Hall, K., Kashima, Y., Seymour, J. F., ... Ross, D. (2018). Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leukemia and Lymphoma, 59(2), 406-415. https://doi.org/10.1080/10428194.2017.1337114
Villemagne Sanchez, Lucia A. ; O’Callaghan, Clare ; Gough, Karla ; Hall, Karen ; Kashima, Yoshihisa ; Seymour, John F. ; Schofield, Penelope ; Ross, David. / Patient perceptions of treatment-free remission in chronic myeloid leukemia. In: Leukemia and Lymphoma. 2018 ; Vol. 59, No. 2. pp. 406-415.
@article{75cbe52d9a8244cb9fb1720fc73cc7fb,
title = "Patient perceptions of treatment-free remission in chronic myeloid leukemia",
abstract = "Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81{\%} of participants (95{\%} CI: 72{\%}–89{\%}) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest motivations for TFR included TKI toxicity (n = 26) and convenience (n = 18). The leading reason for reluctance was fear of consequences of stopping TKI (n = 16). Reluctance was often associated with needs for additional information or incomplete understanding of the current data. Understanding patient motivations and concerns is important if TFR is to become a part of CML management.",
keywords = "Chronic myeloid leukemia, quality of life, treatment-free remission, tyrosine kinase inhibitor",
author = "{Villemagne Sanchez}, {Lucia A.} and Clare O’Callaghan and Karla Gough and Karen Hall and Yoshihisa Kashima and Seymour, {John F.} and Penelope Schofield and David Ross",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/10428194.2017.1337114",
language = "English",
volume = "59",
pages = "406--415",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "2",

}

Villemagne Sanchez, LA, O’Callaghan, C, Gough, K, Hall, K, Kashima, Y, Seymour, JF, Schofield, P & Ross, D 2018, 'Patient perceptions of treatment-free remission in chronic myeloid leukemia', Leukemia and Lymphoma, vol. 59, no. 2, pp. 406-415. https://doi.org/10.1080/10428194.2017.1337114

Patient perceptions of treatment-free remission in chronic myeloid leukemia. / Villemagne Sanchez, Lucia A.; O’Callaghan, Clare; Gough, Karla; Hall, Karen; Kashima, Yoshihisa; Seymour, John F.; Schofield, Penelope; Ross, David.

In: Leukemia and Lymphoma, Vol. 59, No. 2, 01.02.2018, p. 406-415.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patient perceptions of treatment-free remission in chronic myeloid leukemia

AU - Villemagne Sanchez, Lucia A.

AU - O’Callaghan, Clare

AU - Gough, Karla

AU - Hall, Karen

AU - Kashima, Yoshihisa

AU - Seymour, John F.

AU - Schofield, Penelope

AU - Ross, David

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81% of participants (95% CI: 72%–89%) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest motivations for TFR included TKI toxicity (n = 26) and convenience (n = 18). The leading reason for reluctance was fear of consequences of stopping TKI (n = 16). Reluctance was often associated with needs for additional information or incomplete understanding of the current data. Understanding patient motivations and concerns is important if TFR is to become a part of CML management.

AB - Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81% of participants (95% CI: 72%–89%) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest motivations for TFR included TKI toxicity (n = 26) and convenience (n = 18). The leading reason for reluctance was fear of consequences of stopping TKI (n = 16). Reluctance was often associated with needs for additional information or incomplete understanding of the current data. Understanding patient motivations and concerns is important if TFR is to become a part of CML management.

KW - Chronic myeloid leukemia

KW - quality of life

KW - treatment-free remission

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85020488026&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1337114

DO - 10.1080/10428194.2017.1337114

M3 - Article

VL - 59

SP - 406

EP - 415

JO - Leukemia and Lymphoma

T2 - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 2

ER -

Villemagne Sanchez LA, O’Callaghan C, Gough K, Hall K, Kashima Y, Seymour JF et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leukemia and Lymphoma. 2018 Feb 1;59(2):406-415. https://doi.org/10.1080/10428194.2017.1337114